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Gene transfer to adult human lung tissue ex vivo
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The potential of gene therapy for treatment of lung disease
remains unrealised. Early model systems often resulted in
promising efficiency of gene transfer, only to prove irreprod-
ucible in the clinic. While problems such as induction of host
immune responses and duration of expression also need to
be addressed, it is now widely believed that alternative, rel-
evant models which more accurately reflect gene transfer
efficiencies in human lungs are urgently required. We report
here on a human lung slice culture system to assess gene
transfer to adult lung epithelium. A lacZ-expressing adeno-
virus (AdCA35lacZ) was used as a reporter vector. A sol-
ution of AdCA35lacZ was instilled via bronchioles into
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Lung diseases such as cystic fibrosis (CF) and a1-anti-
trypsin deficiency, as well as neonatal disorders such as
respiratory distress syndrome and bronchopulmonary
dysplasia, have significant potential for gene therapy
strategies. Current treatment regimens do not have high
success rates but the identification of genes involved in
these diseases has prompted investigations into correc-
tive gene replacement approaches.1 In comparison to
other organs, the lung offers relatively straightforward
access for gene delivery via the trachea, or alternatively
via the pulmonary artery. In the case of CF, gene delivery
vectors such as adenovirus and cationic lipid/liposomes
have successfully produced CFTR protein expression in
humans in vivo with some demonstrable restoration of
chloride transport.2,3 However, vector-related problems
such as target cell specificity, duration of gene
expression, host cell toxicity, ensuring replication defec-
tiveness and immunogenicity have proved difficult to
solve. As a result, despite initial promising results, no
gene therapy drug has yet been approved for human
use.4,5
A recurrent stumbling block has been the inability to
reproduce results in the clinic based on the animal mod-
els and in vitro human systems used to test vectors.
Transfer efficiencies achieved in murine and human pri-
mary epithelial cell cultures are frequently irreproducible
when tested in vivo and most animal models do not
exactly mimic human respiratory disease.6,7 Adenovirus-
mediated gene transfer to primary cultures of human
lung type II cells can be up to 50 times more efficient
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resected lung tissue, a route analogous to clinical adminis-
tration. Following a 1 h incubation, the tissue was inflated
with a 0.4% agarose solution, instilled via the same bronchi-
oles. Once solidified, 500 mm slices of the tissue were pre-
pared and cultured for 4 days. b-Galactosidase staining
revealed lacZ transgene expression in bronchiolar and
alveolar cells of the lung slices throughout the 4 days in cul-
ture. This system, which can also be used to study other
viral and liposome vectors, could prove to be a useful alter-
native model for assessing gene delivery to adult human
lung epithelium. Gene Therapy (2000) 7, 675–678.
than that observed in vivo8 possibly due at least in part
to altered membrane receptor distribution. Furthermore,
uniform expression of adenoviral reporter genes has been
observed in fibroblasts and type II cells in monolayer cul-
tures derived from digested human fetal lungs.9 This con-
trasts with adenovirus-infected cultured fetal human
explants10 and fetal lambs infected intratracheally in
utero11 where epithelial cells expressed reporter genes but
little to no expression was found in mesenchymal cells.
Therefore, while cultured cell monolayers can address
important mechanistic questions, explant culture appears
to provide a more accurate assessment of gene transfer
efficiency and target cell specificity in vivo.
When tested on CF patients, vectors are usually
applied to nasal mucosa. However, not only is this not
the area clinically affected, but one of the cellular recep-
tors involved in adenoviral entry is absent in nasal
mucosa, but present in distal conducting airways.12 This
may account for differences between nasal and pulmon-
ary epithelia in efficiency of gene transfer and demon-
strates the need for more appropriate means of testing
adenoviral and other gene therapy vectors. Few models
of gene delivery using adult human pulmonary tissue
have been reported. These have involved subcutaneous
transplantation of segments of intact human bronchus, or
denuded rodent trachea reseeded with cultured human
bronchial cells, into the flanks of immunodeficient
mice.8,13 Vectors are subsequently delivered to the lumen
of the xenografts via a surgical incision. While gene trans-
fer and expression in bronchial epithelial cells were suc-
cessfully demonstrated in these models, they have not
been widely used, possibly because they are technically
difficult systems.
We have developed a human lung slice culture system
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as an alternative model for assessing gene delivery vec-
tors. With this system, we can closely reproduce clinical
procedures by administration of adenoviral vectors via
bronchioles to adult human lung tissue ex vivo. The tissue
is then sliced and maintained in culture. Gene delivery
and protein expression can subsequently be analysed in
situ. Here, we report on the successful infection of human
lung tissue with an adenoviral reporter vector
(AdCA35lacZ) and subsequent detection of b-galacto-
sidase in the epithelium of cultured lung slices.
Slices were stained for b-galactosidase activity at 24,
48, 72 and 96 h after infection. At each time-point, X-gal
incubation of AdCA35lacZ infected lung slices resulted
in positive staining of bronchiolar and alveolar epithelial
cells (Figure 1a–f). Maximal b-galactosidase gene
expression was apparent by 24 h with an approximate
equivalent overall number of positive cells present at
each time-point. Very occasional staining occurred in
some smooth muscle cells (less than 5% of total positive
cells). No staining occurred at any stage of the culture in
control slices which had been instilled with culture
medium without AdCA35lacZ. In order to compare gene
transfer and expression in this ex vivo slice system with
that found in existing in vivo models, a similar approach
was employed using cultured murine lung slices. Follow-
ing intratracheal instillation of AdCA35lacZ, b-galacto-
sidase activity was observed in bronchiolar and alveolar
epithelial cells within the cultured slices at 24, 48, 72 and
96 h after infection, with little staining of mesenchymal
cells. As with the human slices, maximal activity was
observed at 24 h with a similar distribution pattern of
staining apparent up to 96 h (Figure 1g). No staining
occurred in control slices instilled with culture medium
without AdCA35lacZ. These findings are consistent with
in vivo studies in rodents where adenovirus infection
using similar doses resulted in transgene expression in
the same cell types and at similar frequencies.14,15 This
would indicate that the ex vivo slice system is comparable
with in vivo instillation models.
The benefits of agarose instillation into the tissue are
two-fold. First, the collapse of the airways and airspaces
during slicing and culturing is prevented, resulting in
retention of tissue architecture and corresponding main-
tenance of cell–cell and cell–matrix contacts. Epithelial
cell polarity and associated localisation of cell surface
receptors are important factors during adenoviral infec-
tion of cells. The lung slice model is, therefore, more rep-
resentative of in vivo epithelia than cultured monolayers,
and is a more relevant model for viral infectivity. Second,
because the agarose is mixed with culture medium, nutri-
ents are delivered throughout the tissue and cells are not
entirely dependent upon nutrient diffusion from the
external culture medium. A limiting factor of the system
is the relatively short culture period of 4 days. After this
time, epithelial cell death is apparent in both control and
infected slices. Optimisation of the culture conditions,
such as improving the culture medium or altering the
agarose solution, should extend the culture period. We
have successfully established a culture system in which
murine lung slices can be cultured for up to 3 weeks with
good retention of tissue architecture and cell viability, by
adapting previously published methods.16,17 Achieving
similar lengths of culture for human slices will permit
further studies of duration of transgene expression.
This is a unique model system for assessment of gene
delivery to distal adult human respiratory epithelium.
This region of the lung has not been represented in any
other in vivo/ex vivo human model of gene delivery to
date, but it is affected by most of the diseases advocated
as suitable for gene therapy. Studies using human fetal
lung tissue have demonstrated gene transfer to noncili-
ated epithelial cells lining the acinar tubules, including
type II cells and their glycogen-rich precursors.10,11 The
extrapolation that gene transfer would occur in corre-
sponding cell types in distal adult human lung is
confirmed in our model.
While an adenoviral vector was used in these experi-
ments, the system is equally applicable to other viral and
liposome vectors. The ability to delivery genes to adult
human lung tissue ex vivo followed by culture and deter-
mination of gene delivery and expression in situ should
enable us to address some of the outstanding problems
hindering progress with gene therapy. Vector-related
issues such as target cell specificity, efficacy of gene deliv-
ery, appropriate vector solute composition and vector
toxicity may be explored using this system, before
clinical tests.
The critical problem of adenovirus-associated immuno-
genicity cannot be assessed in this model under present
conditions. However, among those researchers who are
currently assessing the impasse at which gene therapy
for lung disease now seems to be, many believe that inef-
ficiency of gene transfer is a significant hurdle to be over-
come, and that alternative model systems are required
for more accurate assessments of vectors.4,5 The ex vivo
human lung slice system described here can potentially
contribute to our understanding and development of
gene therapy vectors.
A replication deficient (E1 deleted), sero type 5 aden-
ovirus containing the LacZ reporter gene under the con-
trol of the murine CMV promoter (AdCA35LacZ) was
used.18 The virus was propagated and titrated as pre-
viously described.19 Stock virus was aliquoted and stored
at - 70° C before use.
Macroscopically normal human lung tissue from an
uninvolved lobe was obtained following pneumonec-
tomy for lung cancer and stored at 4° C in 1:1 mixture of
M-199 medium (Gibco, Life Technologies, Paisley, UK)
and Hams F-12 (Gibco) before use. For most of our
experiments, including the data presented here, lung
tissue was stored for no longer than 4 h at 4 ° C. While we
have also infected tissue following overnight storage at
4° C and observed lacZ staining in slices cultured from
this tissue, cell death was increased in tissue which had
been stored overnight and instillation of solutions was
more difficult. A cannula and syringe were used to instil
1 · 109 p.f.u. of AdCA35lacZ suspended in culture
medium (see below), or a control solution (culture
medium only), via exposed bronchioles. Tissues were
incubated, submerged in culture medium (1:1 M-199
medium and Hams F-12 medium, supplemented with 1
mg/ml insulin, 0.5 mg/ml transferrin, 0.1 mg/ml hydro-
cortisone, 10 ng/ml EGF, 0.1 mg/ml retinyl acetate, 2 mm
l-glutamine and 0.1 mg/ml Pen/Strep) at 37° C for 1 h.
A 0.4% agarose solution (1:1 mixture of 0.8% molten
agarose/H2O and 2 · culture medium, maintained at
37° C) was then instilled into the tissues via the same
bronchioles used for adenovirus instillation. Following
incubation at 4° C for 20 min to permit agarose solidifi-
cation, tissues were cut into strips approximately 0.75 cm
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Figure 1 Human lung tissue was infected with AdCA35lacZ (1 · 109 p.f.u.) and cultured slices were stained for b-galactosidase expression. At 24 h
after infection, staining of (a) and (b) alveolar and (c) bronchiolar (arrow) epithelial cells was observed. Slices stained at 96 h after infection displayed
similar staining of (d) and (e) alveolar and (f) bronchiolar (arrows) epithelial cells. Murine lungs were infected intratracheally with AdCA35lacZ (1 · 109
p.f.u.). Epithelial cells within the cultured slices were positive for b-galactosidase expression at each time-point, including (g) 96 h shown here. Magnifi-
cation: (a) and (d): · 100; (b), (c), (e) and (f): · 400; (g): · 200.
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in diameter, embedded in 3% agarose and sliced into 500
mm thick sections using a Krumdieck Tissue Slicer
(Alabama R & D Corporation, Munford, AL, USA). The
embedding agarose detached easily from the slices once
cut. Slices were cultured at the liquid–air interface in six-
well plate Netwell inserts (Costar; Corning, High
Wycombe, UK) in culture medium and incubated at 37 ° C
in humidified 5% CO2.
Mice approximately 5 weeks old were killed by intra-
peritoneal injection of pentabarbitone. Lungs were per-
fused with saline via the pulmonary artery with simul-
taneous artificial ventilation of the lungs using a syringe
and cannula inserted into the trachea. Intact lungs and
trachea were then removed and 0.8 ml culture medium
(see above) containing 1 · 109 p.f.u. of AdCA35lacZ was
instilled into the lungs via the trachea. Lungs were incu-
bated, submerged in culture medium, at 37° C for 1 h. 0.8
ml 0.4% agarose solution was then instilled into the lungs
via the trachea, allowed to solidify and individual lobes
were embedded, sliced and cultured as described above.
Slices were rinsed in PBS, fixed for 5 min in 0.05% glut-
araldehyde at 4 ° C, and then rinsed twice in PBS for 10
min. Slices were then incubated in X-gal solution (20 mm
NaH2PO4, 250 mm Na2HPO4, 1.3 mm MgCl2, 3 mm
K3Fe(CN)6, 3 mm K4Fe(CN)6, 1 mg/ml X-gal (dissolved
in dimethylformamide) in H2O) at 37° C in a humidified
chamber. Staining was visible after 1 h and the reaction
was stopped after 6 h by removing the staining solution
and rinsing the slices with PBS. Tissues were embedded
in paraffin and 3 mm sections were cut and stained with
haematoxylin and eosin.
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